What Is Zhengye Biotechnology Holding L (ZYBT) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Zhengye Biotechnology Holding L presents a highly debated valuation profile at its current price of $0.71. The composite intrinsic value is estimated at $0.89 (+25.8% average upside), masking a wide model spread between the 7 bullish models and 6 bearish models. Model dispersion is worth noting: Bayesian DCF targets $1.98 (+178.9%), versus ML-RIV at $0.25 (-64.3%). This +243.2% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About ZYBT?
13 of 13 models are currently active for ZYBT. Of these, 7 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates ZYBT's intrinsic value at $1.98, implying +178.9% upside from the current price. See which stocks rank higher →
How Does ZYBT Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, ZYBT ranks #35 by Quality of Company score. CirclFi's QOC score of 8.0/10 evaluates 32 fundamental signals. A score of 8.0 places ZYBT in the top tier.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Zhengye Biotechnology Holding L competes in an environment where revenue per drug often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is ZYBT a Value Trap?
The Value Trap algorithm is not active for ZYBT. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for Zhengye Biotechnology Holding L. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Zhengye Biotechnology Holding L is rated at 8.0/10. This strong-tier score demonstrates strong fundamentals across the majority of our quality signals.
The gap between the most bullish and bearish model spans +243.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ZYBT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ZYBT's 13 active models, average confidence is 44%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad